Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
Current and future disease-modifying therapies in multiple sclerosis.
A full genome search in multiple sclerosis.
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
Interferon Beta-1b may reverse axonal dysfunction in multiple sclerosis.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Interferon beta for secondary progressive multiple sclerosis.
Translating Fatigue to Human Performance.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
New insights into signaling during myelination in zebrafish.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
The immunopathology of multiple sclerosis: an overview.
Impact of MS during the critical window of brain development.
Biogen Idec completes purchase of full rights and control of Tysabri®
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.

Pages